Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents ALAFCO
Mandate

Vinge represents ALAFCO

April 14, 2021 Banking and Finance Aviation

Vinge has advised ALAFCO in connection with leasing of a brand new Airbus A320-NEO to SAS, delivered by Airbus from the production facility in Hamburg on 14 April 2021.

Vinge has advised ALAFCO Aviation Lease and Finance Company, a Kuwait-based, world-leading actor in the aviation leasing business, in connection with its leasing of an Airbus A320-NEO, the new, more energy-efficient narrow-body airplane, to Scandinavian Airlines Systems Denmark-Norway-Sweden (SAS). In addition, Vinge administered the registration of the airplane with the Swedish Transportation Authority’s Swedish Aviation Register and negotiated with SAS’s Swedish counsel in connection with the transaction.

Vinge’s team consisted of responsible partner Fredrik Wilkens, project manager Henrik Schön  as well as Anton Sjökvist and Elias Bohlin.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026